Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database

OBJECTIVE: Anti–tumor necrosis factor (anti‐TNF) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti‐TNF agents are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated,...

Descripción completa

Detalles Bibliográficos
Autores principales: Clowse, Megan E. B., Scheuerle, Angela E., Chambers, Christina, Afzali, Anita, Kimball, Alexa B., Cush, John J., Cooney, Maureen, Shaughnessy, Laura, Vanderkelen, Mark, Förger, Frauke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174965/
https://www.ncbi.nlm.nih.gov/pubmed/29623679
http://dx.doi.org/10.1002/art.40508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174965/
https://www.ncbi.nlm.nih.gov/pubmed/29623679
http://dx.doi.org/10.1002/art.40508

Ejemplares similares